Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On February 3, 2022 Akoya Biosciences, Inc. (Nasdaq: AKYA) ("Akoya"), The Spatial Biology Company, reported that it will be virtually participating in the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference (Press release, Akoya Biosciences, FEB 3, 2022, View Source [SID1234607676]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Brian McKelligon, CEO, and Joe Driscoll, CFO, are scheduled to present on Tuesday, February 15th, 2022 at 1 p.m. ET.

BTIG hosted events are intended for prospective and existing BTIG clients only. To listen to the live event, please contact your BTIG representative with interest.

On February 3, 2022 Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, reported that it will participate in two upcoming virtual investor conferences (Press release, Arvinas, FEB 3, 2022, View Source [SID1234607691]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Guggenheim Oncology Conference on Thursday, February 10. Ian Taylor, Ph.D., Chief Scientific Officer, will participate in a fireside chat. A live audio webcast of the presentation will be available here and on the Events + Presentations section of the Company’s website.

2022 SVB Leerink Global Healthcare Conference on Friday, February 18. John Houston, Ph.D., President and Chief Executive Officer, will participate in a fireside chat. A live audio webcast of the presentation will be available here and on the Events + Presentations section of the Company’s website.

On February 3, 2022 Promega reported that Researchers from Johns Hopkins University have shown that a new panel of long mononucleotide repeats (LMR) might offer advantages over traditional microsatellite instability (MSI) detection methods in certain types of solid tumors (Press release, Promega, FEB 3, 2022, View Source [SID1234607711]). The study, published in the February issue of Journal of Molecular Diagnostics, is the first to use the PCR-based Promega LMR MSI Analysis System to detect MSI in endometrial, prostate and other cancers.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Detecting Microsatellite Instability

MSI analysis measures changes in the length of specific DNA sequences that occur because of a deficiency in a cell’s DNA mismatch repair system. MSI status is a valuable indicator for predicting whether an individual might respond to immune checkpoint inhibitor therapy. The Promega MSI Analysis System, Version 1.2 is the current gold standard for PCR-based MSI testing and has been relied upon by global clinical researchers for nearly two decades. The assay amplifies a panel of five mononucleotide repeat markers, each composed of 21-27 repeated adenine bases. This technology is used in the OncoMate MSI Dx Analysis System, which is available as a CE-IVD in Europe and an FDA-cleared IVD medical device in the United States.

The LMR MSI Analysis System, launched in February 2021, consists of eight markers – four of the gold standard markers, plus four novel LMR markers that have 52-60 repeated adenine bases each. Longer markers are typically more "unstable," or prone to replication errors, so it has been hypothesized that this new panel of markers might offer greater sensitivity for MSI detection in cancers where the results are otherwise inconclusive or ambiguous.

LMR Analysis Research

The research group led by Dr. James Eshleman, M.D., Ph.D. validated the LMR MSI panel using colorectal, endometrial, and prostate tumor samples, as well as a variety of other tumor samples with inconclusive results in previous MSI testing.

Statistics for the LMR MSI panel include:

Colorectal cancer: 100% accuracy, 100% clinical sensitivity, 100% clinical specificity
Endometrial cancer: 98% accuracy, 98% clinical sensitivity, 100% clinical specificity
Prostate cancer: 75% clinical sensitivity
Other cancers: 100% concordance between LMR MSI and MSI V1.2 in 22 samples previously designated MSI-High
"The new LMR panel clearly offers unique benefits in certain cancer types," says Jeff Bacher, Senior Research Scientist at Promega and co-author on the study. "These results are encouraging for the detection of microsatellite instability in samples that were previously difficult or impossible."

The paper states that the Johns Hopkins researchers will continue using the MSI Analysis System, Version 1.2 for detecting MSI in colorectal cancer, and they have adopted the LMR MSI Analysis System for endometrial, prostate and other non-GI cancers.

To learn more about the LMR MSI Analysis System, visit www.promega.com/LMRAnalysis

Promega Clinical Research Program

This study was supported in part by the Promega Clinical Research Program (PCRP), a global initiative that supports researchers using Promega technologies to advance clinical diagnostics. This is the first publication to result from a PCRP partnership, and seven more projects are currently benefitting from Promega products and expertise.

On February 3, 2022 Minomic International Ltd. reported that it is the beneficiary of a tranche of co-investment from the Advanced Manufacturing Growth Centre’s (AMGC) Commercialisation Fund and the Federal Government’s Modern Manufacturing Initiative (Press release, Minomic, FEB 3, 2022, https://www.minomic.com/federal-government-funding-to-boost-commercialisation-of-minomics-micheck-prostate/ [SID1234607729]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

One of 24 successful applicants, Minomic and its partners will commit a total of $793,856 towards the project, with $396,928 of these funds from AMGC. The investment will assist in commercialising MiCheck Prostate that is designed to detect life threatening aggressive prostate cancer in its early stages.

MiCheck Prostate overcomes the low accuracy of conventional screening tests to reduce unnecessary intervention such as painful biopsies and improve overall management of the patient.

The co-investment will boost Minomic’s commercial activities in Australia where it sees a need for a more effective test to detect prostate cancer here and abroad.

Minomic CEO Brad Walsh welcomed the announcement, "Our application was successful due to the fact the product is market-ready and addresses a critical need; the funding will help us accelerate the process.

The test addresses an unmet need for urologists which is a test with enhanced specificity to reduce unnecessary and painful biopsies and augment the MRI workflow.

Fewer biopsies will reduce patient’s anxiety, pain and the risk of drug-resistant infections.

The pandemic has shown the importance of boosting local innovation and sovereign capability in the biotech sector. Credit to the federal government for recognising this and we would like to thank them and AMGC for their support."

Managing Director for the Advanced Manufacturing Growth Centre, Dr Jens Goennemann said, "Minomic’s innovative MiCheck Prostate cancer test will revolutionise the way we test, detect and treat prostate cancer, both locally and abroad.

Minomic’s product demonstrates the breadth and depth of manufacturing talent we have in Australia and proves that by investing in all stages of manufacturing from pre-production and production to post-production, we can develop world leading products for global markets."